share_log

22nd Century Applauds FDA Proposal to Mandate Reduced Nicotine Content in Cigarettes

22nd Century Applauds FDA Proposal to Mandate Reduced Nicotine Content in Cigarettes

22世纪对FDA提案表示赞赏,该提案要求在香烟中减少尼古丁含量。
newsfile ·  12/12 10:31

Recent FDA Action Advances Policy Proposal That Originated During First Trump Administration and Continued to Progress Under Biden Administration

最近FDA的行动推动了在特朗普首任政府期间提出的政策提案,并在拜登政府下持续推进。

Mocksville, North Carolina--(Newsfile Corp. - December 12, 2024) - 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today announced that it applauds action by the U.S. Food and Drug Administration to advance its long-standing proposal mandating a drastic reduction in the amount of nicotine in cigarettes, a cornerstone goal of public health experts seeking to reduce the harms of smoking.

北卡罗来纳州莫克斯维尔--(Newsfile CORP. - 2024年12月12日) - 22nd Century Group, Inc. (纳斯达克: XXII),一家烟草制品公司,致力于与尼古丁作斗争,并认为吸烟者应该对其尼古丁消费有选择权,今天宣布,对美国食品和药物管理局推动其长期提案表示赞赏,该提案要求大幅减少香烟中的尼古丁含量,这是公共卫生专家寻求减少吸烟危害的核心目标。

"We are excited to see definitive action by the FDA intended to advance its scientifically backed reduced nicotine content mandate for cigarette products, a non-partisan proposal that actually began moving forward during the first Trump administration and continued its progress during the Biden administration," said Larry Firestone, Chief Executive Officer of 22nd Century Group.

22nd Century的首席执行官拉里·法尔斯通表示:"我们很高兴看到FDA采取明确行动推动其基于科学的香烟产品低尼古丁含量法规,这是一个跨党派的提案,实际上是在特朗普首任政府期间开始推进的,并在拜登政府期间继续取得进展。"

"22nd Century has played a pivotal role in this effort following 26 years of research and product development as a key supplier for reduced nicotine content research cigarettes used in the numerous federally funded studies to generate a massive body of scientific evidence in support of this policy. 22nd Century also has the first and only FDA authorized reduced nicotine content cigarette designed specifically to reduce the harms of smoking."

"22nd Century在这项工作中发挥了关键作用,经过26年的研究和产品开发,作为低尼古丁含量研究香烟的主要供应商,参与了众多联邦资助的研究,生成了大量科学证据支持该政策。22nd Century还拥有第一个也是唯一一个FDA授权的低尼古丁含量香烟,专门设计用于减少吸烟的危害。"

"VLN reduced nicotine content cigarettes from 22nd Century, which are available in thousands of stores across the country, have shown that this product can be an important tool for adult smokers seeking to control their nicotine intake. We are now in the process of launching additional products, including VLN SKUs within key customer brand families, as part of our drive to expand the distribution of reduced nicotine content cigarettes manufactured by 22nd Century. Adding VLN within other brand families is a straightforward way to reduce our time to market, increase consumer awareness and expand the VLN footprint.

"22nd Century的VLN低尼古丁含量香烟在全国数千家商店都有销售,已经证明该产品可以成为成人吸烟者控制尼古丁摄入的重要工具。我们现在正在推出更多产品,包括在关键客户品牌系列中推出的VLN SKU,作为扩大22nd Century生产的低尼古丁含量香烟分销的努力的一部分。在其他品牌系列中增加VLN是一种简单的方式,可以缩短我们的市场时间,增加消费者意识,并扩大VLN的影响。"

"With still almost half a million premature deaths in the U.S. attributed to smoking each year, we fully support the FDA in advocating for the significant potential harm reduction that could come from a reduced nicotine content cigarette mandate."

“在美国,每年因吸烟导致的过早死亡人数仍接近五十万,我们全力支持FDA倡导减少尼古丁含量香烟法规可能带来的显著潜在危害降低。”

About 22nd Century Group, Inc.

关于22nd Century Group, Inc.

22nd Century Group is the pioneering nicotine harm reduction company in the tobacco industry enabling smokers to take control of their nicotine consumption.

22nd Century Group是烟草行业中开创性的尼古丁危害减少公司,帮助吸烟者控制他们的尼古丁消费。

We created our flagship product, the VLN cigarette, to give traditional cigarette smokers an authentic and familiar alternative that helps them take control of their nicotine consumption. VLN cigarettes have 95% less nicotine than the traditional cigarette and have been proven to greatly reduce nicotine consumption. Instead of offering new ways of delivering nicotine to addicted smokers, we offer smokers the option to take control of their nicotine consumption and make informed and more productive choices, including the choice to avoid addictive levels of nicotine altogether.

我们创造了我们的旗舰产品VLN香烟,为传统香烟吸烟者提供一种真实且熟悉的替代选择,帮助他们 控制他们的尼古丁消费。VLN香烟的尼古丁含量比传统香烟低95%,并已被证明能大大减少尼古丁消费。我们不是为上瘾的吸烟者提供新的尼古丁输送方式,而是为吸烟者提供控制他们的尼古丁消费、做出知情且更有效选择的机会,包括选择完全避免上瘾水平的尼古丁。

Our wholly owned subsidiaries include a leading cigarette manufacturer that produces all VLN products and provides turnkey contract manufacturing for other tobacco brands both domestically and internationally. The 60,000 square foot facility in Mocksville, North Carolina has the capacity to produce more than 45 million cartons of combusted tobacco products annually with additional space for expansion.

我们的全资子公司包括一家领先的香烟制造商,生产所有VLN产品,并为其他烟草品牌提供交钥匙合同制造服务,涵盖国内和国际市场。位于北卡罗来纳州莫克斯维尔的6万平方英尺的设施每年可以生产超过4500万箱燃烧烟草制品,并有额外空间用于扩展。

Our proprietary reduced nicotine tobacco blends are made possible by comprehensive and patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, resulting in full flavor and high yield with 95% less nicotine. Our extensive patent portfolio has been developed to ensure we have the only low nicotine combustible cigarette in the United States and critical international markets.

我们的专有低尼古丁烟草混合物得益于授权技术,调节烟草植物中尼古丁生物合成活性,最终实现95%低尼古丁的全面风味和高产量。我们的广泛专利组合旨在确保我们在美国及关键国际市场上拥有唯一的低尼古丁可燃香烟。

VLN and Helps You Smoke Less are registered trademarks of 22nd Century Limited LLC.

VLN和降低吸烟量的Helps You Smoke Less是22nd century Limited LLC的注册商标。

Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

了解更多请访问 xxiicentury.com,在 X(前身为Twitter),在 LinkedIn,并且在 YouTube.

Learn more about VLN at tryvln.com.

了解更多关于VLN的信息。 tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的警示说明

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024, and in the Company's Quarterly Reports filed on May 15, 2024 and August 13, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

除了历史信息之外,本文稿中的所有陈述、预期和假设都是前瞻性陈述,包括但不限于我们全年的业务展望。前瞻性陈述通常包含诸如“预计”、“相信”、“考虑”、“继续”、“可能”、“估计”、“期待”、“探讨”、“预测”、“目标”、“指导”、“意图”、“可能”、“可能”、“计划”、“潜在”、“预测”、“初步”、“可能”、“项目”、“有希望”、“寻求”、“应该”、“将会”、“会”等类似表达。前瞻性陈述包括但不限于关于(i)我们成本削减举措的陈述,(ii)对监管执行的预期,包括我们获得新规豁免的能力,(iii)我们的财务和运营表现以及(iv)我们对业务中断保险索赔的预期。实际结果可能与前瞻性陈述中明确或隐含的内容有重大差异。可能导致实际结果与前瞻性陈述有重大差异的重要因素在于2024年3月28日提交的公司年度报告(表格10-k)中的“风险因素”部分,以及在2024年5月15日和2024年8月13日提交的公司季度报告中。本文稿中提供的所有信息均为截至本日期的信息,公司不承担任何义务,也不打算更新这些前瞻性陈述,除非法律要求。

Investor Relations & Media Contact

投资者关系与媒体联系方式

Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

马特·克雷普斯
投资者关系
22世纪集团
mkreps@xxiicentury.com
214-597-8200

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发